43 Papers
186 Citations
Lei Chen is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 13, co-authored 35 publications. Previous affiliations of Lei Chen include University of Texas Health Science Center at San Antonio & University of Texas at Austin.
Chat about Author
Papers
Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome.
Steven A. Gustafson,Pei Lin,Su S. Chen,Lei Chen,Lynne V. Abruzzo,Rajyalakshmi Luthra,L. Jeffrey Medeiros,Sa A. Wang +7 more
TL;DR: It is suggested that t-AML-t(8;21) shares many features with de novo AML- t( 8;21)(q22;q22), but affected patients have a worse outcome.
Immunoglobulin gamma heavy chain gene with somatic hypermutation is frequently expressed in acute myeloid leukemia.
Xiangguo Qiu,Xiangguo Qiu,X Sun,Z He,J Huang,F Hu,Lei Chen,P Lin,M J You,L J Medeiros,C C Yin +10 more
TL;DR: The findings suggest that AMl-derived IgG may be a novel AML-related gene that contributes to leukemogenesis and AML progression and may serve as a useful molecular marker for monitoring minimal residual disease or designing target therapy.
44
•Journal Article
Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.
Sadhna Dhingra,Michelle E. Rodriguez,Qi Shen,Xuizhen Duan,Melissa L. Stanton,Lei Chen,Rongzhen Zhang,Robert E. Brown +7 more
TL;DR: The results show significant activation with overexpression of phosphorylated mTORC2 complex in uterine leiomyosarcoma (ULMS) and smooth muscle tumors of uncertain malignant potential (STUMP) as evidenced by nuclear localization of p-mTOR (Ser 2448) in ULMS and STUMP and insight into their tumorigenic mechanisms.
44
Rearrangement and expression of the immunoglobulin μ-chain gene in human myeloid cells
TL;DR: AML-derived IgM might be a novel AML-related molecule that is involved in leukemogenesis and AML progression and might serve as a useful molecular marker for designing targeted therapy and monitoring minimal residual disease.
Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations
TL;DR: It is concluded that acute myeloid leukemia associated with t(8;21) is a heterogeneous disease with poor survival in a subset of patients unrelated to common secondary cytogenetic aberrations.
39